Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This study is an investigator-initiated clinical study to evaluate the safety and
tolerability of melphalan hydrochloride for injection in patients with relapsed or relapsed
refractory multiple myeloma. Using the "3 + 3" dose escalation principle, 3-6 subjects per
dose were enrolled, depending on the dose limiting toxicity (DLT) observed in the first cycle
of chemotherapy for each subject. After completing the 21-day assessment of the first cycle
of chemotherapy, if there was no DLT, the study started for the next dose group.